Mochida ReFeel デジタル神経損傷用
デジタル神経損傷に対するReFeelの影響を評価する研究者主導の観察臨床研究プロジェクト。
This is an Investigator Led single-center, Prospective and Observational, Clinical Research Project. The specific aim of this study is to test/observe the safety and effectiveness of the ReFeel Device for Digital nerve injury in improving recovery time and outcomes. The primary objective of this study is to monitor clinical and surgical procedural outcomes for the use of ReFeel device.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
ReFeel is indicated for the repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity, or the management of peripheral nerve injuries in which there has been no substantial loss of nerve tissue.
ReFeel is a device used in applications for patients with peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity, or the management of peripheral nerve injuries in which there has been no substantial loss of nerve tissue.
Despite this common injury there is continued debate on the best treatment algorithm for digital nerve injuries. Digital nerve repair is usually not an option as the field of injury is too large for direct repair. Both conduits and nerve allograft have been used with varying success. Nerve conduits have traditionally been used for gaps less than 2 cm, with allograft for larger gaps.
ReFeel has received 510(k) clearance for a new alginate-based nerve cuff. We propose to conduct an Investigator-led Observational Clinical Research of ReFeel for patients treated with alginate nerve cuff to assess the clinical function following reconstruction.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28207
- OrthoCarolina Research Institute
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18-69 years
- Digital nerve injury in at least one digit requiring repair with a gap of 1-25mm
- Able to provide tension free end to end nerve coaptation
- Have uninjured contralateral or adjacent digit that is suitable to serve as a referenced digit for baseline functional assessments.
- Willing to comply with follow up for visits up to 12 months.
Exclusion Criteria:
- Estimated distance of recovery greater than 150 mm (from proximal site of to the tip of the digit)
- Injury distal to distal interphalangeal joint
- Extensive soft tissue injury that will impair recovery assessment
- Incomplete nerve transections
- Injury requiring replantation of the target digit
- Injuries to the affected nerve proximal to the superficial arch
- Nerve injuries > 24 weeks after initial injury
- End to side nerve repair
- Injuries with vascular damage resulting in inadequate perfusion despite repair
- Subjects with type 1 diabetes or type 2 diabetes requiring regular insulin therapy
- Subjects who are undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other know treatment that affects the growth of neural and/or vascular system
- History of neuropathy, diabetic neuropathy, or another known neuropathy
- Excepted use of medication during the study that is known to impact nerve regeneration or cause peripheral neuropathy such as immunosuppressant's and Chemotherapeutic
- History of chronic ischemic condition of the upper extremity.
- Workers Compensation
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の:ReFeel device
Subjects who enroll in this study will receive ReFeel device for Digital nerve injury |
ReFeel is indicated for the repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity, or the management of peripheral nerve injuries in which there has been no substantial loss of nerve tissue. ReFeel is a device used in applications for patients with peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity, or the management of peripheral nerve injuries in which there has been no substantial loss of nerve tissue. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Static two-point discrimination
時間枠:Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months
|
Presented in millimetres and in ASSH designation (less than 6 mm 'normal', 6-10 mm 'fair', and 11 to 15 mm 'poor') |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 12 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Visual Analog Scale (VAS)
時間枠:Baseline, 2 weeks, 6 weeks, 12 weeks, 3 months, 6 months, 12 months
|
Pain Score (1-10, 1 being the best and 10 being the worst pain) |
Baseline, 2 weeks, 6 weeks, 12 weeks, 3 months, 6 months, 12 months
|
|
Water emersion testing
時間枠:2 weeks, 6 weeks, 12 weeks, 3 months, 6 months, 12 months
|
Recommend patients submerge injured hand into water until other digits wrinkle. Report weekly if finger wrinkles like non-injured digits. |
2 weeks, 6 weeks, 12 weeks, 3 months, 6 months, 12 months
|
|
Physician Satisfaction Score
時間枠:Operative
|
Scale 0-5, with 0 being very difficult and 5 being very Easy the best score |
Operative
|
|
How many nerves were repaired with the provided graft sheet?
時間枠:Operative
|
How many nerves were repaired with the provided graft sheet? |
Operative
|
|
Change in Range of Motion (ROM)
時間枠:Baseline, 2 weeks, 6 weeks, 12 weeks, 3 months, 6 months, 12 months
|
Change in Range of Motion (ROM) of the injured digit, measured in degrees, from baseline |
Baseline, 2 weeks, 6 weeks, 12 weeks, 3 months, 6 months, 12 months
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Glenn Gaston, MD、OrthoCarolina Research Institute
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 9220 (ReFeel - 0001)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
To be determined at a later date.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。